Loading stock data…
$8.46-0.18 (-2.03%)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
Benitec Biopharma Inc. in the Healthcare sector is trading at $8.46 with a market capitalization of $295M. Wall Street consensus targets $24.33 (6 analysts), implying a +187.8% move over the next 12 months. The stock is currently near its 52-week low of $8.31, remaining 28.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | $0 |
| Operating Income | -$13.58M↓ | -$13.38M↓ | -$9.80M↑ | -$17.18M↓ | -$15.34M |
| Net Income | -$11.94M↓ | -$11.84M↓ | -$8.96M↑ | -$16.15M↓ | -$14.50M |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines th...